Business
Lonza's Synaffix Collaborates with Qurient Therapeutics to Enable Development of Dual-Payload ADC
Synaffix B.V. ("Synaffix"), a Lonza company (SWX:LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with potential best-in-class therapeutic index, today jointly announced that it has entered into a licensing agreement with Qurient Co., Ltd., a clinical-stage biopharmaceutical company based in South Korea, for the development of a dual-payload ADC.
About this update from Qurient Co., Ltd.
[{"type":"list","items":[{"val":[{"type":"text","content":"License agreement centered around technology enabling dual-payload ADC","length":75,"tagName":"p"}]},{"val":[{"type":"text","content":"Unique combination of Synaffix's exatecan-based technology with Qurient's CDK7 inhibitor ","length":101,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":176,"olType":false},{"type":"text","content":"AMSTERDAM and SEONGNAM-SI, South Korea , Sept. 25, 2025 /PRNewswire/ -- Synaffix B.V. ("Synaffix"), a Lonza company (SWX:LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with potential best-in-class therapeutic index, today jointly announced that it has entered into a licensing agreement with Qurient Co., Ltd., a clinical-stage biopharmaceutical company based in South Korea, for the development of a dual-payload ADC.","length":523,"tagName":"p"},{"type":"text","content":"Dual-payload ADCs are designed to deliver two separate cytotoxic agents with distinct mechanisms of action to target cancer cells, aiming to enhance therapeutic efficacy and mitigate payload resistance. Their therapeutic promise can potentially expand the current range of effective treatments while minimizing toxicity to healthy tissues, especially in refractory cancer cases.","length":378,"tagName":"p"},{"type":"text","content":"The collaboration aims to develop a dual-payload ADC consisting of Synaffix's exatecan-based technology and Qurient's CDK7 inhibitor, aiming to target unmet medical needs in solid tumors. Under the terms of the agreement, Qurient will gain access to Lonza's clinical-stage, site-specific ADC technology platform powered by Synaffix services including GlycoConnect® antibody conjugation, HydraSpace® polar spacer, and exatecan-based linker-payload technologies, as well as Lonza's market-leading expertise and experience in developing and manufacturing bioconjugates.","length":582,"tagName":"p"},{"type":"text","content":"Lonza will manufacture components related to its proprietary Synaffix technologies, and Qurient will perform the research, development, manufacturing and commercialization of the ADC, and manufacturing of Qurient's CDK7 inhibitor.","length":234,"tagName":"p"},{"type":"text","content":"Peter van de Sande, Head of Syna...